Bausch Health Companies I... (BHC)
7.47
0.07 (0.95%)
At close: Jan 14, 2025, 3:59 PM
7.48
0.13%
After-hours Jan 14, 2025, 07:00 PM EST
undefined% (undefined)
| Bid | 5 |
| Market Cap | 2.75B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -15.56 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 8 |
| Volume | 3,192,377 |
| Avg. Volume (20D) | 1,584,334 |
| Open | 7.44 |
| Previous Close | 7.40 |
| Day's Range | 7.30 - 7.50 |
| 52-Week Range | 3.96 - 11.46 |
| Beta | undefined |
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...
Sector Healthcare
IPO Date Mar 29, 1994
Employees 20,270
Stock Exchange NYSE
Ticker Symbol BHC
Website https://www.bauschhealth.com
Analyst Forecast
According to 4 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 0.40% from the latest price.
Buy 0.00%
Hold 75.00%
Sell 25.00%
Next Earnings Release
Bausch Health Companies Inc. is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of $2.52B, reflecting a 4.65% YoY growth and earnings per share of 1.14, making a -0.87% decrease YoY.
Analysts project revenue of $2.52B, reflecting a 4.65% YoY growth and earnings per share of 1.14, making a -0.87% decrease YoY.
2 months ago ·
Source
+6.3%
Bausch Health Companies shares are trading higher ...
Unlock content with
Pro Subscription
2 months ago ·
Source
+12.61%
Bausch Health shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 revenue guidance.
